← All trials
NCT04928495
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2021
- Primary completion
- Apr 9, 2022
- Completion date
- Jun 9, 2022
- First posted
- Jun 16, 2021
- Last posted
- Jun 30, 2021
- Enrollment
- 219
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal University of CearaLead sponsor
- Federal University of CearaReponsible party - principal investigator
- Government of BrazilCollaborator
- Leonardo da Vinci Hospital - HLVCollaborator
- Universidade Estadual Paulista Júlio de Mesquita FilhoCollaborator
- São José Hospital for Infectious Diseases - HSJCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.